glp-1 texas North cities grapple with rising drug costs in employee health plans Almost half of GLP-1 users

Description

Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)

Progressive ratio operant responding for sucrose was examined in male and female rats, following GLP-1R activation and pharmacological or genetic GLP-1R blockade in the LH

However, no retrospective epidemiological studies can provide definitive answers, and nausea, vomiting and diarrhoea remain the most clinically relevant adverse effects of these drugs, compromising long-term adherence.

By the end of 2024, GLP-1 volume had surpassed 9M prescriptions

The FDA criticized the maker of Ozempic and Wegovy, Novo Nordisk, for serious violations related to the reporting of possible side effects linked to semaglutide, the active ingredient in the drug